Switzerland-based Novartis has developed a new anti-malaria drug, GanLum, that showed 97% effectiveness in late-stage trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback